Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and ISSA F KHOURI.
HAGOP M KANTARJIAN
Connection Strength
2.788
ISSA F KHOURI
  1. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood Cancer J. 2024 08 07; 14(1):129.
    View in: PubMed
    Score: 0.245
  2. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 05; 99(5):836-843.
    View in: PubMed
    Score: 0.237
  3. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol. 2023 05 02; 16(1):44.
    View in: PubMed
    Score: 0.224
  4. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 04; 98(4):658-665.
    View in: PubMed
    Score: 0.220
  5. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol. 2023 03; 98(3):493-501.
    View in: PubMed
    Score: 0.219
  6. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038.
    View in: PubMed
    Score: 0.194
  7. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
    View in: PubMed
    Score: 0.184
  8. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302.
    View in: PubMed
    Score: 0.141
  9. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30.
    View in: PubMed
    Score: 0.123
  10. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7.
    View in: PubMed
    Score: 0.055
  11. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022 03 24; 139(12):1908-1919.
    View in: PubMed
    Score: 0.052
  12. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893.
    View in: PubMed
    Score: 0.052
  13. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389.
    View in: PubMed
    Score: 0.049
  14. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656.
    View in: PubMed
    Score: 0.049
  15. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749.
    View in: PubMed
    Score: 0.048
  16. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789.
    View in: PubMed
    Score: 0.047
  17. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999 Nov; 10(11):1293-9.
    View in: PubMed
    Score: 0.044
  18. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387.
    View in: PubMed
    Score: 0.044
  19. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9.
    View in: PubMed
    Score: 0.041
  20. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017 Jul 01; 28(7):1554-1559.
    View in: PubMed
    Score: 0.037
  21. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2017 07; 31(7):1654-1657.
    View in: PubMed
    Score: 0.037
  22. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467.
    View in: PubMed
    Score: 0.036
  23. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
    View in: PubMed
    Score: 0.035
  24. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant. 1996 May; 17(5):775-9.
    View in: PubMed
    Score: 0.035
  25. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53.
    View in: PubMed
    Score: 0.033
  26. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood. 1995 Jun 01; 85(11):3257-63.
    View in: PubMed
    Score: 0.032
  27. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014 Nov 13; 124(20):3059-64.
    View in: PubMed
    Score: 0.031
  28. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant. 1994 Jul; 14(1):57-61.
    View in: PubMed
    Score: 0.030
  29. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.
    View in: PubMed
    Score: 0.030
  30. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200.
    View in: PubMed
    Score: 0.028
  31. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther. 1992 Apr; 3(2):137-45.
    View in: PubMed
    Score: 0.026
  32. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007 Oct; 48(10):1931-9.
    View in: PubMed
    Score: 0.019
  33. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Feb; 39(3):157-64.
    View in: PubMed
    Score: 0.018
  34. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20; 24(15):2343-51.
    View in: PubMed
    Score: 0.017
  35. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5.
    View in: PubMed
    Score: 0.012
  36. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000 Sep; 39(1-2):77-85.
    View in: PubMed
    Score: 0.012
  37. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol. 2000 May; 18(9):1831-6.
    View in: PubMed
    Score: 0.011
  38. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6.
    View in: PubMed
    Score: 0.009
  39. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996 Mar; 100(3):299-307.
    View in: PubMed
    Score: 0.009
  40. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 01; 86(11):4337-43.
    View in: PubMed
    Score: 0.008
  41. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br J Haematol. 1992 Dec; 82(4):708-14.
    View in: PubMed
    Score: 0.007
  42. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation. Prog Clin Biol Res. 1992; 377:227-30.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.